| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
| [2] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
|
| [3] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma[J].J Hepatol, 2018, 69(1):182-236.
|
| [4] |
Cheng S, Chen M, Cai J, et al. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 Edition)[J]. Liver Cancer, 2020, 9(1):28-40.
|
| [5] |
Benson AB, D'Angelica MI, Abbott DE, et al. Guidelines insights: Hepatobiliary Cancers, Version 2.2019[J]. J Natl Compr Canc Netw, 2019, 17(4):302-310.
|
| [6] |
Im JH, Yoon SM, Park HC, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis ina hepatitis B endemic area[J]. Liver Int, 2017, 37(1):90-100.
|
| [7] |
Xi M, Zhang L, Zhao L, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis[J]. PLoS One, 2013, 8(5): e63864.
|
| [8] |
Lo CH, Yang JF, Liu MY, et al. Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy[J]. PLoS One, 2017, 12(5):e0177793.
|
| [9] |
Matsuo Y, Yoshida K, Nishimura H, et al. Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis/inferior vena cava tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy[J]. J Radiat Res, 2016, 57(5):512-523.
|
| [10] |
Shui Y, Yu W, Ren X, et al. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis[J]. Radiat Oncol, 2018, 13(1):188.
|
| [11] |
Lou J, Li Y, Liang K, et al. Hypofractionated radiotherapy asa salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis[J]. BMC Cancer, 2019, 19(1):668.
|
| [12] |
Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion:a randomized clinical trial[J]. JAMA Oncol, 2018, 4(5):661-669.
|
| [13] |
Choi BO, Choi IB, Jang HS, et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis[J]. BMC Cancer, 2008(8):351.
|
| [14] |
Shen L, Xi M, Zhao L, et al. Combination therapy after TACE for hepatocellular carcinoma with macroscopic vascular invasion: stereotactic body radiotherapy versus sorafenib[J]. Cancers, 2018, 10(12):516.
|
| [15] |
Choi HS, Kang KM, Jeong BK, et al. Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease[J]. Asia Pac J Clin Oncol, 2021, 17(3):209-215.
|
| [16] |
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021，7(1):6.
|
| [17] |
Brade AM, Ng S, Brierley J, et al. Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2016, 94(3):580-587.
|
| [18] |
Que J, Wu HC, Lin CH, et al. Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis[J]. Medicine, 2020, 99(13):e19660.
|
| [19] |
Munoz-Schuffenegger P, Barry A, Atenafu EG, et al. Stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion[J]. Radiother Oncol, 2021, 156:120-126.
|
| [20] |
Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, et al. Stereotactic radiotherapy for hepatocellular carcinoma, radiosensitization strategies and radiation-immunotherapy combination[J]. Cancers, 2021, 13(2):192.
|
| [21] |
Friedman D, Baird JR, Young KH, et al. Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma[J]. Hepatol Res, 2017, 47(7):702-714.
|
| [22] |
Lasley FD, Mannina EM, Johnson CS, et al. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy[J]. Pract Radiat Oncol, 2015, 5(5):e443-449.
|
| [23] |
Chino F, Stephens SJ, Choi SS, et al. The role of external beam radiotherapy in the treatment of hepatocellular cancer[J]. Cancer, 2018, 124(17):3476-3489.
|
| [24] |
Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization[J]. Cancer, 2012, 118(21):5424-5431.
|
| [25] |
Mastrocostas K, Jang HJ, Fischer S, et al. Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls[J]. Abdom Radiol, 2019, 44(5): 1795-1807.
|
| [26] |
Price TR, Perkins SM, Sandrasegaran K, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma[J]. Cancer, 2012, 118(12):3191-3198.
|